That's the one thing that still doesn't add up for

That's the one thing that still doesn't add up for me. How did little old AMBS get so lucky with Lympro, Nuropro, MSPrecise, ESS, and G-Town licenses? You can't tell me that the folks selling or trading basically for cash or shares of AMBS didn't know what they had. Did they go to BP and ask them to purchase or partner? One would have to think so, wouldn't you?

Granted AMBS must have one hell of a sales pitch to get 4-5 potential huge money makers. At this point I wouldn't pin it as luck by any means. I doubt there's huge flaws with any of them. Maybe they're time sensitive in some cases as far as getting it to market and get paid before the next latest and greatest thing comes out, but that's it imo.

Looks like most Bio's are getting waxed today so this could just be part of today's bloodbath. I have faith in this company long term. However, I will have to decide if I want to gamble on missing the proverbial train by swing trading AMBS more often than not.

Or maybe the street thinks this is all great news but it's going to cost them to move all these great things along to market. Either way, right now I'm tired of watching the paint dry, water boil, and grass grow. Someone let me know when the Mona Lisa is done, dinner is served, and it's time for harvest.